PTK2 and neoplasm: In vivo pharmacologic FAK inhibitor treatment of various solid cancers resulted in stroma normalization by impacting angiogenesis, immune cell recruitment, CAF activation and ECM production, altogether leading to decreased tumor progression, aggressiveness and chemoresistance [301,302,303,304,305,306,307,308,309,310,311,312].